Melanoma and Skin Cancer Trials Limited

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Role: collaborator

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Role: lead

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Role: lead

Targeted Therapy and Avelumab in Merkel Cell Carcinoma

Role: lead

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Role: collaborator

Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)

Role: lead

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Role: lead

Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma

Role: lead

Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients

Role: lead

Neurotropic Melanoma of the Head and Neck

Role: lead

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Role: lead

Radiotherapy & Combi in Metastatic Melanoma

Role: lead

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

Role: lead

Radiotherapy or Imiquimod in Complex Lentigo Maligna

Role: lead

Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.

Role: collaborator

Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Role: lead

Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI)

Role: lead

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma

Role: lead